Case Study

One-Day First Participant Visits and Low Screen Fail Rates for a Pneumococcal Study

Tekton delivered a Phase 3 pneumococcal vaccine study at sites in Edmond, Oklahoma, and Austin, Texas, with rapid regulatory and activation timelines. The Edmond site was approved to overenroll and then quickly exceeded its goal.

  • 1-day regulatory turnaround from receipt to submission
  • 1 day from greenlight to first participant visit at both sites
  • 6.1% combined screen-failure rate
  • Enrollment goal met or exceeded

Talk to Tekton

senior-couple-embrace

About This Study

TRIAL
Phase 3 pneumococcal vaccine study
SITE LOCATIONS
Edmond, OK, and Austin, TX

Partner With Tekton

Join leading Sponsors and CROs that trust Tekton's sites to support their most important clinical trials.

Complete the form on this page or email to discuss your protocol, target population, timelines, and site needs.

Submit Your Information